The Genetics

Dietikon, Switzerland Founded: 1998 • Age: 28 yrs
Develops and commercializes small molecule inhibitors for cancer and Alzheimers disease therapies.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products 3 Services tracked
Competitors 7 Brand Intelligence

About The Genetics

The Genetics is a company based in Dietikon (Switzerland) founded in 1998. It operates as a B2B. The Genetics offers products and services including Small Molecule Wnt-Inhibitors, Small Molecule BACE Inhibitors, and Small Molecule Growth Inhibitors. The Genetics operates in a competitive market with competitors including AmerisourceBergen, Xantis Pharma, DCS Pharma, RUWAG and Globomedica, among others.

  • Headquarter Dietikon, Switzerland
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of The Genetics

The Genetics offers a comprehensive portfolio of products and services, including Small Molecule Wnt-Inhibitors, Small Molecule BACE Inhibitors, and Small Molecule Growth Inhibitors.

Product name locked
Category locked
Primary

Inhibitors targeting Wnt pathway for colorectal cancer treatment

Product name locked
Category locked
Locked

Inhibitors reducing amyloid production for Alzheimer's disease

Product name locked
Category locked
Locked

Inhibitors for controlling cellular growth in cancer

Funding Insights of The Genetics

Premium access

Detailed funding history for The Genetics

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by The Genetics

Investments
Premium access

Investment portfolio details for The Genetics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - The Genetics

Premium access

Detailed financials for The Genetics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

The Genetics Comparisons

The Genetics Primary company
Description
Develops and commercializes small molecule inhibitors for ca...
Location
Dietikon, Switzerland
Founded Year
1998
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for The Genetics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of The Genetics

The Genetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AmerisourceBergen, Xantis Pharma, DCS Pharma, RUWAG and Globomedica, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Pharmaceutical distribution and supply chain services are provided globally.
Locked Locked Locked
Distributor of generic prescription and over-the-counter products
Locked Locked Locked
Pharmaceutical products are distributed by DCS Pharma in Switzerland.
Locked Locked Locked
Distributor of drugs
Locked Locked Locked
Diversified pharmaceutical drugs are distributed by Globomedica in Switzerland.
Locked Locked Locked
Serves as a diversified distributor in the healthcare sector.
Premium access

Detailed competitors of The Genetics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on The Genetics

Premium access

Complete news archive for The Genetics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about The Genetics

The Genetics was founded in 1998.

The Genetics is headquartered in Dietikon, Switzerland. It is registered at Dietikon, Zurich, Switzerland.

The GENETICS Company is a biopharmaceutical firm specializing in research, development, and commercialization of small molecule inhibitors. It targets therapies for colorectal cancer, Alzheimers disease, and other cancers by optimizing molecular pathways. Based in Paris, France, the company focuses on innovative treatments through scientific advancements and aims to provide solutions for patients via partnerships with healthcare entities. Their work involves identifying and testing compounds to address disease mechanisms.

The Genetics's top competitors include AmerisourceBergen, DCS Pharma and RUWAG.

The Genetics offers Small Molecule Wnt-Inhibitors, Small Molecule BACE Inhibitors, and Small Molecule Growth Inhibitors.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available